Mon, June 27, 2022
Fri, June 24, 2022
Thu, June 23, 2022

Judah Frommer Maintained (SRPT) at Hold with Decreased Target to $90 on, Jun 24th, 2022

Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $95 to $90 on, Jun 24th, 2022.

Judah has made no other calls on SRPT in the last 4 months.



There are 3 other peers that have a rating on SRPT. Out of the 3 peers that are also analyzing SRPT, 1 agrees with Judah's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $74 on, Thursday, May 19th, 2022


These are the ratings of the 2 analyists that currently disagree with Judah


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $107 on, Tuesday, April 19th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $150 on, Wednesday, March 2nd, 2022